04:17 PM EDT, 03/31/2025 (MT Newswires) -- Ascendis Pharma ( ASND ) late Monday said it filed a new drug application with the US Food & Drug Administration for the company's TransCon CNP drug candidate to treat children with achondroplasia.

According to Ascendis, TransCon CNP is an investigational prodrug of C-type natriuretic peptide administered once weekly and designed to treat achondroplasia, a disorder that keeps cartilage from changing into bone in children.

The new drug application follows recent clinical testing of TransCon CNP during three double-blind, placebo-controlled trials and up to three years of open-label extension studies.

Ascendis also expects to submit its marketing authorization application to the European Medicines Agency later this year.